Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Conditions:   Head and Neck Basaloid Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Head and Neck Cancer;   Oropharyngeal Cancer;   HNSCC
Interventions:   Biological: Cetuximab;   Drug: Ficlatuzumab;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   University of Arizona;   National Cancer Institute (NCI)
Recruiting

http://ift.tt/2GRYgUi